Real Madrid star Kylian Mbappe hospitalized with gastroenteritis at the Club World Cup
MIAMI (AP) — Real Madrid forward Kylian Mbappe has been hospitalized with an acute case of gastroenteritis, the Spanish club said Thursday.
World Cup winner Mbappe missed Madrid's opening game at the Club World Cup against Saudi Arabian team Al Hilal in Miami on Wednesday because of a fever.
Advertisement
Coach Xabi Alonso said he hoped the France international would be available for the team's next game against Pachuca on Sunday. But his hospitalization casts doubt over what part he might be able to play in the monthlong tournament in the United States.
'Our player Kylian Mbappé is suffering from an acute case of gastroenteritis and has been admitted to hospital in order to undergo a series of tests and follow the appropriate course of treatment,' Madrid said in a statement.
___
James Robson is at https://twitter.com/jamesalanrobson
___
AP soccer: https://apnews.com/hub/soccer
James Robson, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Pep Guardiola hints at new Manchester City role for Phil Foden in 2025/26 season
Phil Foden could be set to take on a new role in Manchester City's system, as hinted by head coach Pep Guardiola this week. The England international returned to action for the new 2025/26 season with a bang as he provided both a goal and an assist in Manchester City's opening victory of the FIFA Club World Cup in the United States. Advertisement Scoring inside the opening two minutes, Foden inspired his side on to a convincing victory over Wydad AC in the group stage of the competition, before delivering the perfect corner for Jeremy Doku to volley home before the stroke of half-time. With Kevin De Bruyne departing the club and Manchester City recruiting Rayan Cherki from Lyon for the number 10 role, many have been wondering how that could impact Phil Foden's positional availability in Pep Guardiola's side. Operating through the middle alongside the aforementioned France international, Wednesday afternoon perhaps offered the first glimpse into the all-energy approach that Guardiola is attempting to implement in his forward line. And speaking to broadcasters after Manchester City's 2-0 win over Wydad AC in their opening contest of the Club World Cup, Pep Guardiola was quizzed on the importance of Foden after his match-winning performance in Philadelphia. Advertisement 'Of course he will be important [this season],' Guardiola insisted. The Catalan tactician continued, 'He plays another role, more there, we have a lot of No10s, we have to adjust many things, but step by step.' For now, it remains to be seen exactly what Pep Guardiola's preference is for the attacking midfield ranks in his side, although the remainder of the Club World Cup could offer some insight into the vision for the new season. Manchester City will next take on the United Arab Emirates' Al Ain on matchday two of the group stage, with the Middle-Eastern club falling to a tough 0-5 defeat on their own opening game of the competition at the hands of Juventus. Pep Guardiola has already stated that the clash against the side in Atlanta, Georgia at the weekend could see a heavily rotated line-up fielded, with as many as 10 new players anticipated for the contest.
Washington Post
12 minutes ago
- Washington Post
Dodgers set franchise attendance record, surpassing 2 million fans in just 40 games
LOS ANGELES — The Los Angeles Dodgers have surpassed 2 million in attendance in just 40 games this season. The defending World Series champions have had 2,026,238 through the gates so far. The team said Wednesday that it's the fastest they've reached that mark in franchise history. Last season, it took 42 games and in 2019, when the Dodgers set their all-time season attendance mark of 3,974,309, it took 43 games.
WebMD
13 minutes ago
- WebMD
FDA Approves First Twice-Yearly Shot to Prevent HIV
June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012, the drug – known as lenacapavir but sold under the name Yeztugo – offers a new way to protect against this life-threatening infection that affects more than a million people in the U.S. and has no cure. The shot is given before potential exposure to the virus. HIV spreads through unprotected sex and shared needles (including dirty needles from tattoos and body piercings). It weakens the immune system, and in its advanced stage, the body can no longer fight off infections, leading to acquired immune deficiency syndrome (AIDS). Only about a third of eligible people in the U.S. use available HIV prevention, with especially low use among women, Black/African American and Hispanic communities, and people in the South. This is mainly due to stigma, low awareness about existing options, and challenges with daily pills or frequent shots. Carlos del Rio, MD, a distinguished professor of medicine in the Division of Infectious Diseases at Emory University School of Medicine, said that getting a shot just twice a year could make it easier for people to stick with prevention. "Yeztugo could be the transformative PrEP [pre-exposure prophylaxis] option we've been waiting for – offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic," said del Rio, who is also co-director of the Emory Center for AIDS Research in Atlanta. Gilead, the drug's maker, said the FDA approved Yeztugo based on two major studies, which showed that it worked better than taking a daily pill form of PrEP in preventing HIV with a nearly 100% success rate. In one trial, none of the 2,134 women who received Yeztugo got HIV, while in the other, only two out of 2,179 people did. It was well tolerated with no new safety concerns, which led the academic journal Science to name lenacapavir as its 2024 "Breakthrough of the Year." Yeztugo attacks a protective shell that HIV needs to stay alive, which helps stop the virus from growing and spreading. Most HIV drugs only work at one part of the virus's life cycle, but Yeztugo works at several points. It also still works even if other HIV drugs have stopped working. It is given as a shot under the skin and is only for people who test negative for HIV. Before starting Yeztugo and before each shot, your provider will test for HIV to prevent the virus from developing resistance to the medication. The treatment begins with two shots and two tablets, followed by two more tablets the next day – then continues with one shot every six months. If a shot is delayed by over two weeks, a weekly pill can be used for up to six months. If over 28 weeks pass with no treatment, patients may need to restart. If a patient gets HIV while on Yeztugo, they'll need full HIV treatment, as Yeztugo alone isn't enough. Yeztugo helps lower the risk of HIV when taken as prescribed, along with safe sex practices like using condoms.
